Kidneys are one of the most hardworking organs of the human body. Various types of health conditions like diabetes can be highly harmful for kidneys. Though there are treatments to treat chronic kidney diseases. With the medical advancements, now there have been advancements in treatments for chronic kidney disease,
In people with chronic kidney disease, dapagliflozin which is a sodium glucose co-transporter is used to minimize the risk of renal function decline, kidney failure, cardiovascular mortality, and heart failure hospitalization. The DAPA-CKD trail is a game changer for the patients’ cardiorenal disease prevention and progression.
Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) plus a sodium-glucose cotransporter 2 (SGLT2) inhibitor should be used to treat patients with type 2 diabetes and diabetic kidney disease (DKD).
In a major trial of individuals with type 2 diabetes and severe DKD, finerenone, a nonsteroidal selective mineralocorticoid receptor antagonist (MRA), was demonstrated to reduce the course of renal function loss.